Arcus Biosciences Gross Profit 2017-2023 | RCUS
Arcus Biosciences gross profit from 2017 to 2023. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Arcus Biosciences Annual Gross Profit
(Millions of US $) |
| 2022 |
$112 |
| 2021 |
$383 |
| 2020 |
$78 |
| 2019 |
$15 |
| 2018 |
$8 |
| 2017 |
$1 |
| 2016 |
$ |
Arcus Biosciences Quarterly Gross Profit
(Millions of US $) |
| 2023-03-31 |
$25 |
| 2022-12-31 |
$34 |
| 2022-09-30 |
$34 |
| 2022-06-30 |
$27 |
| 2022-03-31 |
$18 |
| 2021-12-31 |
$355 |
| 2021-09-30 |
$9 |
| 2021-06-30 |
$9 |
| 2021-03-31 |
$9 |
| 2020-12-31 |
$10 |
| 2020-09-30 |
$65 |
| 2020-06-30 |
$2 |
| 2020-03-31 |
$2 |
| 2019-12-31 |
$10 |
| 2019-09-30 |
$2 |
| 2019-06-30 |
$2 |
| 2019-03-31 |
$2 |
| 2018-12-31 |
$2 |
| 2018-09-30 |
$4 |
| 2018-06-30 |
$1 |
| 2018-03-31 |
$1 |
| 2017-12-31 |
$1 |
| 2017-09-30 |
$0 |
| 2017-06-30 |
|
| 2017-03-31 |
|
| 2016-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.536B |
$0.112B |
|
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
|
